JP2022534420A - 眼のタンパク質凝集疾患を治療するための薬剤 - Google Patents

眼のタンパク質凝集疾患を治療するための薬剤 Download PDF

Info

Publication number
JP2022534420A
JP2022534420A JP2021570895A JP2021570895A JP2022534420A JP 2022534420 A JP2022534420 A JP 2022534420A JP 2021570895 A JP2021570895 A JP 2021570895A JP 2021570895 A JP2021570895 A JP 2021570895A JP 2022534420 A JP2022534420 A JP 2022534420A
Authority
JP
Japan
Prior art keywords
alkyl
cap4349
hydrogen
acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021570895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534420A5 (enExample
Inventor
プラサド，スリドハー・ゴビンダ
ピーターマン，マーシャル・クラーク
シンハ，サントシュ
Original Assignee
プレックス ファーマスーティカルズ，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレックス ファーマスーティカルズ，インク filed Critical プレックス ファーマスーティカルズ，インク
Publication of JP2022534420A publication Critical patent/JP2022534420A/ja
Publication of JP2022534420A5 publication Critical patent/JP2022534420A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021570895A 2019-05-31 2020-06-01 眼のタンパク質凝集疾患を治療するための薬剤 Pending JP2022534420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855560P 2019-05-31 2019-05-31
US62/855,560 2019-05-31
PCT/US2020/035592 WO2020243720A1 (en) 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye

Publications (2)

Publication Number Publication Date
JP2022534420A true JP2022534420A (ja) 2022-07-29
JP2022534420A5 JP2022534420A5 (enExample) 2023-06-09

Family

ID=73553335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570895A Pending JP2022534420A (ja) 2019-05-31 2020-06-01 眼のタンパク質凝集疾患を治療するための薬剤

Country Status (8)

Country Link
US (1) US20220241247A1 (enExample)
EP (1) EP3976017A4 (enExample)
JP (1) JP2022534420A (enExample)
CN (1) CN114173771A (enExample)
BR (1) BR112021024151A2 (enExample)
CA (1) CA3141998A1 (enExample)
MX (1) MX2021014682A (enExample)
WO (1) WO2020243720A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512116A (ja) * 2020-01-28 2023-03-23 プロテゴ バイオファーマ， インコーポレイテッド トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
WO2023278604A1 (en) * 2021-06-29 2023-01-05 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
WO2023009585A2 (en) * 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530842A (ja) * 2011-10-24 2014-11-20 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112913A1 (en) * 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
WO2013038351A1 (en) * 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
BR112015021836A2 (pt) * 2013-03-08 2017-07-18 Allergan Inc conjugados de antibióticos diretamente ligados com drogas esteroides
US9789091B2 (en) * 2013-03-14 2017-10-17 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530842A (ja) * 2011-10-24 2014-11-20 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEIRAO, M. ET AL., AMYLOID, vol. 18, no. 3, JPN6024021082, 2011, pages 92 - 97, ISSN: 0005466871 *
SUGIOKA, K. ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 488, no. 3, JPN6024021083, 2017, pages 483 - 488, ISSN: 0005466870 *

Also Published As

Publication number Publication date
WO2020243720A9 (en) 2021-02-04
MX2021014682A (es) 2022-04-06
EP3976017A4 (en) 2023-06-14
WO2020243720A1 (en) 2020-12-03
US20220241247A1 (en) 2022-08-04
CN114173771A (zh) 2022-03-11
CA3141998A1 (en) 2020-12-03
BR112021024151A2 (pt) 2022-02-08
EP3976017A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
JP5743326B2 (ja) サーチュインモジュレーターとしてのクロメノンアナログ
JP2022171977A (ja) 毒性アルデヒド関連疾患および処置
US20220241247A1 (en) Pharmacological agents for treating protein aggregation diseases of the eye
JP5628828B2 (ja) チアゾロピリジンサーチュイン調節化合物
JP2021008473A (ja) 細胞生存率を向上させるための組成物およびその使用方法
US20180050989A1 (en) Aldehyde trapping compounds and uses thereof
US20110256064A1 (en) Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
CA3032609A1 (en) Aldehyde trapping compounds and methods of use thereof
JP4234430B2 (ja) チオールを含むｎａａｌａｄアーゼ抑制物質
CN104193740A (zh) 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
EA021938B1 (ru) Хинолины и их аналоги в качестве модуляторов сиртуина
GB2144993A (en) Ophthalmic anti-inflammatory agents
US20200276211A1 (en) Compounds for treating near vision disorders
US20160000746A1 (en) Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues
WO2007037188A1 (ja) 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
WO2020213693A1 (ja) リポ酸プロドラッグ
EP3213751A1 (en) Phacosclerosis inhibitor
US7511036B2 (en) Dihydrothiazine prodrugs of thiazolium agents
JP3496111B2 (ja) 涙液分泌促進および角結膜障害治療剤
JP7158466B2 (ja) てんかん、神経変性疾患、及び他のｃｎｓ疾患を治療するための化合物
TW202330510A (zh) 對老花眼等之治療或預防有用之含硫化合物
JPH06500328A (ja) ５―リポキシゲナーゼインヒビターとしてのフェノール性チオエーテルアミド
HK40123243A (en) Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors
KR20250051358A (ko) 항노화용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241122